LIFR and hepatocellular carcinoma: In clinical practice, the leukemia inhibitory factor receptor (LIFR) + CD34 combination had a useful differential diagnostic model for well-differentiated HCC and HGDN with a sensitivity and specificity of 93.5% and 90.5%, respectively [62].